{
  "thread": {
    "uuid": "eefb3e2db875b6308f98ef1933449e75a6098c27",
    "url": "https://www.morningstar.com/news/dow-jones/202401056720/ligand-pharmaceuticals-gets-fda-ok-for-viral-skin-infection-treatment",
    "site_full": "www.morningstar.com",
    "site": "morningstar.com",
    "site_section": "http://www.morningstar.com",
    "site_categories": [
      "financial_news",
      "finance"
    ],
    "section_title": "Morningstar | Empowering Investor Success",
    "title": "Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment | Morningstar",
    "title_full": "Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment | Morningstar",
    "published": "2024-01-05T02:00:00.000+02:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "US",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 2121,
    "domain_rank_updated": "2024-01-02T12:06:49.000+02:00",
    "reach": null,
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "gplus": {
        "shares": 0
      },
      "pinterest": {
        "shares": 0
      },
      "linkedin": {
        "shares": 0
      },
      "stumbledupon": {
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "eefb3e2db875b6308f98ef1933449e75a6098c27",
  "url": "https://www.morningstar.com/news/dow-jones/202401056720/ligand-pharmaceuticals-gets-fda-ok-for-viral-skin-infection-treatment",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": null,
  "published": "2024-01-05T02:00:00.000+02:00",
  "title": "Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment | Morningstar",
  "text": "By Ben Glickman\nLigand Pharmaceuticals said its treatment for molluscum, a viral skin infection, had received approval from U.S. regulators.\nThe company said Friday that the U.S. Food and Drug Administration had approved Zelsuvmi, a topical prescription medication, to treat moluscum in adults and children one year old or older.\nLigand expects the treatment to be available in the U.S. in the second half of 2024.\nThe company said the FDA had approved Zelsuvmi as the first novel drug to treat mollescum infections.\nMolluscum is a contagious skin infection which can cause lesions. It primarily affects children.\nWrite to Ben Glickman at ben.glickman@wsj.com\n(END) Dow Jones Newswires\nJanuary 05, 2024 17:25 ET (22:25 GMT)\nCopyright (c) 2024 Dow Jones & Company, Inc. Evaluate the market like an analyst. Subscribe to Morningstar Investor today. Start Free Trial Market Updates More Market Updates Can 2023′s Blockbuster Stock Market Rally Continue? Sarah Hansen 12 hours ago What’s Happening In the Markets This Week Bella Albrecht 169 days ago Strong December Jobs Report Surprises, but Overall Labor Market Is Slowing Sarah Hansen 13 hours ago Why We Expect the Job Market’s Slowdown to Renew in 2024 Preston Caldwell 128 days ago December U.S. Jobs Report: Payrolls 216,000, Stronger Than Expected Sarah Hansen 17 hours ago Want to Lose Your Money? Listen to Millionaires. John Rekenthaler 1 days ago December Jobs Forecasts Point to a Strong but Cooling Labor Market Sarah Hansen 2 days ago 15 Charts On the Surprise ‘Everything Rally’ for 2023 Tom Lauricella 6 days ago Stock Picks More Stock Picks Betting Big on Stocks Rarely Beats Boring Investing Jack Shannon 17 days ago Consumer Defensives: Moaty Operators Well-Positioned to Navigate Competitive Landscape Erin Lash, CFA 1 days ago Industrials: Sector Is Fairly Valued, but We Still See Compelling Investment Opportunities Brian Bernard, CFA, CPA 1 days ago Utilities: Will the Sector Reset or Repeat In 2024? Travis Miller 2 days ago Healthcare: Valuations Look Attractive Across Almost All Industries Damien Conover, CFA 2 days ago The Worst-Performing Stocks of 2023 Bella Albrecht 3 days ago Consumer Cyclicals: Discounts Retain Their Allure Erin Lash, CFA 2 days ago Basic Materials: As Sector Underperforms, We See Strong Opportunities Seth Goldstein, CFA 2 days ago",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Human Interest",
    "Health",
    "Science and Technology"
  ],
  "external_links": [],
  "external_images": [],
  "entities": {
    "persons": [
      {
        "name": "sarah hansen",
        "sentiment": "none"
      },
      {
        "name": "zelsuvmi",
        "sentiment": "none"
      },
      {
        "name": "ben glickman",
        "sentiment": "none"
      },
      {
        "name": "bella albrecht",
        "sentiment": "none"
      }
    ],
    "organizations": [
      {
        "name": "fda",
        "sentiment": "negative"
      },
      {
        "name": "ligand pharmaceuticals",
        "sentiment": "negative"
      },
      {
        "name": "ben glickman ligand pharmaceuticals",
        "sentiment": "negative"
      },
      {
        "name": "morningstar investor",
        "sentiment": "none"
      },
      {
        "name": "ligand",
        "sentiment": "none"
      },
      {
        "name": "dow jones & company, inc",
        "sentiment": "none"
      },
      {
        "name": "u.s. food and drug administration",
        "sentiment": "none"
      }
    ],
    "locations": [
      {
        "name": "u.s.",
        "sentiment": "none"
      }
    ]
  },
  "rating": null,
  "crawled": "2024-01-06T00:38:35.485+02:00",
  "updated": "2024-01-06T08:44:07.736+02:00"
}